IsoRay, Inc. (AMEX:ISR) is reporting first quarter earnings results on Tuesday 10th November 2020, after market close.
The consensus estimates from Thomson Reuters are loss of $ 0.01 per share.
For the full year, analysts predict revenues of $ 12.24 million, while looking forward to loss of $ 0.04 per share.
The Company Outlook
Revenue for 1Q21 are expected in a range of $ 2.30 million ~ $ 2.50 million
Click Here For More Historical Outlooks Of IsoRay, Inc.
Previous Quarter Performance
IsoRay, Inc. reported loss for the fourth quarter of $ 0.02 per share, from the revenue of $ 2.28 million. The quarterly revenues gained 18.75 percent compared with the same quarter last year. Street analysts expected IsoRay, Inc. to report loss of $ 0.01 per share on revenue of $ 2.70 million for the fourth quarter. The bottom line results missed street analysts by $ 0.01 or 100 percent, at the same time, top line results fell short of analysts by $ 0.42 million or 15.56 percent.
Stock Performance
Shares of IsoRay, Inc. traded up $ 0.02 or 5.32 percent on Monday, reaching $ 0.42 with volume of 502.40 thousand shares. IsoRay, Inc. has traded high as $ 0.42 and has cracked $ 0.39 on the downward trend
According to the previous trading day, closing price of $ 0.42, representing a 29.03 % increase from the 52 week low of $ 0.31 and a 62.26 % decrease over the 52 week high of $ 1.06.
The company has a market capital of $ 36.63 million and is part of the Healthcare sector and Medical Instruments & Supplies industry.
Conference Call
IsoRay, Inc. will be hosting a conference call at 4:30 PM eastern time on 10th November 2020, to discuss its 1Q21 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.isoray.com
IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed.
